A proteome resource of ovarian cancer ascites: Integrated proteomic and bioinformatic analyses to identify putative biomarkers

Journal of Proteome Research

Volumn 7, Issue 1, 2008, Pages 339-351

  Gortzak Uzan, Limor ^a   Ignatchenko, Alex ^a   Evangelou, Andreas I ^a   Agochiya, Mahima ^a   Brown, Kevin A ^a   St Onge, Peter ^a   Kireeva, Inga ^a   Schmitt Ulms, Gerold ^a   Brown, Theodore J ^b,c   Murphy, Joan ^a,b   Rosen, Barry ^a,b   Shaw, Patricia ^a   Jurisica, Igor ^a,b   Kislinger, Thomas ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Ascites; Bioinformatics; Biomarker; Body fluids; Integrative Computational Biology; Microarray; Ovarian cancer; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ACCURACY; ARTICLE; ASCITES; BIOINFORMATICS; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FILTER; HUMAN; MICROARRAY ANALYSIS; OVARY CANCER; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; URINE;

ASCITES; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; FEMALE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 38649104431     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0703223     Document Type: Article

References (85)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56 (2), 106-130.
2. Sankaranarayanan, R.; Ferlay, J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 2006, 20 (2), 207-225.
3. Abramov, Y.; Anteby, S. O.; Fasouliotis, S. J.; Barak, V. The role of inflammatory cytokines in Meigs' syndrome. Obstet. Gynecol. 2002, 99 (5 Pt 2), 917-919.
4. Davidson, B.; Reich, R.; Kopolovic, J.; Berner, A.; Nesland, J. M.; Kristensen, G. B.; Trope, C. G.; Bryne, M.; Risberg, B.; van de Putte, G.; Goldberg, I. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin. Exp. Metastasis 2002, 19 (2), 135-144.
5. Fang, X.; Yu, S.; Bast, R. C.; Uu, S.; Xu, H. J.; Hu, S. X.; LaPushin, R.; Claret, F. X.; Aggarwal, B. B.; Lu, Y.; Mills, G. B. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem. 2004, 279 (10), 9653-9661.
6. Feldman, G. B.; Knapp, R. C.; Order, S. E.; Hellman, S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 1972, 32 (8), 1663-1666.
7. Zebrowski, B. K.; Yano, S.; Liu, W.; Shaheen, R. M.; Hicklin, D. J.; Putnam, J. B., Jr.; Ellis, L. M. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 1999, 5 (11), 3364-8336.
8. Berchuck, A.; Carney, M. Human ovarian cancer of the surface epithelium. Biochem. Pharmacol. 1997, 54 (5), 541-544.
9. Bookman, M. A. Biological therapy of ovarian cancer: current directions. Semin. Oncol. 1998, 25 (3), 381-396.
10. Westermann, A. M.; Beijnen, J. H.; Moolenaar, W. H.; Rodenhuis, S. Growth factors in human ovarian cancer. Cancer Treat. Rev. 1997, 23 (2), 113-131.
11. Mills, G. B.; May, C.; McGill, M.; Roifman, C. M.; Mellors, A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988, 48 (5), 1066-1071.
12. Adachi, J.; Kumar, C.; Zhang, Y.; Olsen, J. V.; Mann, M. The human urinary proteome contains more than 1500 proteins including a large proportion of membranes proteins. GenomeBiology 2006, 7 (9), R80.
13. Omenn, G. S.; States, D. J.; Adamski, M.; Blackwell, T. W.; Menon, R.; Hermjakob, H.; Apweiler, R.; Haab, B. B.; Simpson, R. J.; Eddes, J. S.; Kapp, E. A.; Moritz, R. L.; Chan, D. W.; Rai, A. J.; Admon, A.; Aebersold, R.; Eng, J.; Hancock, W. S.; Hefta, S. A.; Meyer, H.; Paik, Y. K.; Yoo, J. S.; Ping, P.; Pounds, J.; Adkins, J.; Qian, X.; Wang, R.; Wasinger, V.; Wu, C. Y.; Zhao, X.; Zeng, R.; Archakov, A.; Tsugita, A.; Beer, I.; Pandey, A.; Pisano, M.; Andrews, P.; Tammen, H.; Speicher, D. W.; Hanash, S. M. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5 (13), 3226-3245.
14. Xu, Y.; Shen, Z.; Wiper, D. W.; Wu, M.; Morton, R. E.; Elson, P.; Kennedy, A. W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA, J. Am. Med. Assoc. 1998, 280 (8), 719-723.
15. Gericke, B.; Raila, J.; Sehouli, J.; Haebel, S.; Konsgen, D.; Mustea, A.; Schweigert, F. J. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005, 5, 133.
16. Kislinger, T.; Cox, B.; Kannan, A.; Chung, C.; Hu, P.; Ignatchenko, A.; Scott, M. S.; Gramolini, A. O.; Morris, Q.; Hallett, M. T.; Rossant, J.; Hughes, T. R.; Frey, B.; Emili, A. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006, 125 (1), 173-186.
17. Kislinger, T.; Gramolini, A. O.; Pan, Y.; Rahman, K.; MacLennan, D. H.; Emili, A. Proteome dynamics during C2C12 myoblast differentiation. Mol. Cell. Proteomics 2005, 4 (7), 887-901.
18. Kislinger, T.; Rahman, K.; Radulovic, D.; Cox, B.; Rossant, J.; Emili, A. PRISM, a generic large scale proteomic investigation strategy for mammals. Mol. Cell. Proteomics 2003, 2 (2), 96-106.
19. Washburn, M. P.; Wolters, D.; Yates, J. R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19 (3), 242-247.
20. Sun, H.; Fang, H.; Chen, T.; Perkins, R.; Tong, W. GOFFA: Gene Ontology For Functional Analysis - A FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinf. 2006, 7 Suppl 2, S23.
21. Brown, K. R.; Jurisica, I. Online predicted human interaction database. Bioinformatics 2005, 21 (9), 2076-2082.
22. Brown, K. R.; Jurisica, I. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome-Biology 2007, 8 (5), R95.
23. Shevchenko, A.; Wilm, M.; Vorm, O.; Mann, M. Mass spectrometric sequencing of proteins silver-stained Polyacrylamide gels. Anal. Chem. 1996, 68 (5), 850-858.
24. Craig, R.; Beavis, R. C. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004, 20 (9), 1466-1467.
25. Kersey, P. J.; Duarte, J.; Williams, A.; Karavidopoulou, Y.; Birney, E.; Apweiler, R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 2004, 4 (7), 1985-1988.
26. Peng, J.; Elias, J. E.; Thoreen, C. C.; Licklider, L. J.; Gygi, S. P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2003, 2 (1), 43-50.
27. Elias, J. E.; Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 2007, 4 (3), 207-214.
28. Kapp, E. A.; Schutz, F.; Connolly, L. M.; Chakel, J. A.; Meza, J. E.; Miller, C. A.; Fenyo, D.; Eng, J. K.; Adkins, J. N.; Omenn, G. S.; Simpson, R. J. An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 2005, 5 (13), 3475-3490.
29. Tabb, D. L.; Fernando, C. G.; Chambers, M. C. MyriMatch: highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis. J. Proteome Res. 2007, 6 (2), 654-661.
30. Adamski, M.; Blackwell, T.; Menon, R.; Martens, L.; Hermjakob, H.; Taylor, C.; Omenn, G. S.; States, D. J. Data management and preliminary data analysis in the pilot phase of the HUPO Plasma Proteome Project. Proteomics 2005, 5 (13), 3246-3261.
31. Adachi, J.; Kumar, C.; Zhang, Y.; Mann, M. In-depth analysis of the adipocyte proteome by mass spectrometry and bioinformatics. Mol. Cell. Proteomics 2007, 6, 1257-1273.
32. Barker, S. D.; Casado, E.; Gomez-Navarro, J.; Xiang, J.; Arafat, W.; Mahasreshti, P.; Pustilnik, T. B.; Hemminki, A.; Siegal, G. P.; Alvarez, R. D.; Curiel, D. T. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol. Oncol. 2001, 82 (1), 57-63.
33. Kislinger, T.; Gramolini, A. O.; MacLennan, D. H.; Emili, A. Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J. Am. Soc. Mass Spectrom. 2005, 16 (8), 1207-1220.
34. Koziol, J. A.; Feng, A. C.; Schnitzer, J. E. Application of capture-recapture models to estimation of protein count in MudPIT experiments. Anal. Chem. 2006, 78 (9), 3203-3207.
35. Liu, H.; Sadygov, R. G.; Yates, J. R., III. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76 (14), 4193-4201.
36. Eng, J. K.; McCormack, A. L.; Yates, J. R. An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J. Am. Soc. Mass Spectrom. 1994, 11, 976-989.
37. Perkins, D. N.; Pappin, D. J.; Creasy, D. M.; Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20 (18), 3551-3567.
38. Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1 (11), 845-867.
39. Gamberoni, G.; Storari, S.; Volinia, S. Finding biological process modifications in cancer tissues by mining gene expression correlations. BMC Bioinf. 2006, 7, 6.
40. Patil, M. A.; Chua, M. S.; Pan, K. H.; Lin, R.; Lih, C. J.; Cheung, S. T.; Ho, C.; Li, R.; Fan, S. T.; Cohen, S. N.; Chen, X.; So, S. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005, 24 (23), 3737-3747.
41. Chen, E. I.; Hewel, J.; Krueger, J. S.; Tiraby, C.; Weber, M. R.; Kralli, A.; Becker, K.; Yates, J. R., III; Felding-Habermann, B. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007, 67 (4), 1472-1486.
42. Engwegen, J. Y.; Gast, M. C.; Schellens, J. H.; Beijnen, J. H. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 2006, 27 (5), 251-259.
43. Gogoi, R.; Srinivasan, S.; Fishman, D. A. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev. Mol. Diagn. 2006, 6 (4), 627-637.
44. Bast, R. C., Jr.; Mug, T. L.; St John, E.; Jenison, E.; Niloff, J. M.; Lazarus, H.; Berkowitz, R. S.; Leavitt, T.; Griffiths, C. T.; Parker, L.; Zurawski, V. R., Jr.; Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983, 309 (15), 883-887.
45. Markman, M. Limitations to the use of the CA-125 antigen level in ovarian cancer. Curr. Oncol. Rep. 2003, 5 (4), 263-264.
46. Fujimoto, J.; Sakaguchi, H.; Hirose, R.; Ichigo, S.; Tamaya, T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 1998, 83 (12), 2528-2533.
47. Yamamoto, S.; Konishi, I.; Mandai, M.; Kuroda, H.; Komatsu, T.; Nanbu, K.; Sakahara, H.; Mori, T. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 1997, 76 (9), 1221-1227.
48. Fishman, D. A.; Bafetti, L. M.; Banionis, S.; Kearns, A. S.; Chilukuri, K.; Stack, M. S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997, 80 (8), 1457-1463.
49. Moser, T. L.; Young, T. N.; Rodriguez, G. C.; Pizzo, S. V.; Bast, R. C., Jr.; Stack, M. S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer 1994, 56 (4), 552-559.
50. Diamandis, E. P.; Yousef, G. M.; Soosaipillai, A. R.; Bunting, P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 2000, 33 (7), 579-583.
51. Dong, Y.; Kaushal, A.; Bui, L.; Chu, S.; Fuller, P. J.; Nicklin, J.; Samaratunga, H.; Clements, J. A. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 2001, 7 (8), 2363-2371.
52. Luo, L. Y.; Bunting, P.; Scorilas, A.; Diamandis, E. P. Human kallikrein 10: a novel tumor marker for ovarian carcinoma, Clin. Chim. Acta 2001, 306 (1-2), 111-118.
53. Cox, B.; Kislinger, T.; Wigle, D. A.; Kannan, A.; Brown, K.; Okubo, T.; Hogan, B.; Jurisica, I.; Frey, B.; Rossant, J.; Emili, A. Integrated proteomic and transcriptomic profiling of mouse lung development and Nmyc target genes. Mol. Syst. Biol. 2007, 3, 109.
54. Makino, E.; Sakaguchi, M.; Iwatsuki, K.; Huh, N. H. Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death. J. Mol. Med. 2004, 82 (9), 612-620.
55. Kikuchi, N.; Horiuchi, A.; Osada, R.; Imai, T.; Wang, C.; Chen, X.; Konishi, I. Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an important autocrine/paracrine factor in tumor progression. Cancer Sci. 2006, 97 (10), 1061-1069.
56. Trachte, A. L.; Suthers, S. E.; Lerner, M. R.; Hanas, J. S.; Jupe, E. R.; Sienko, A. E.; Adesina, A. M.; Lightfoot, S. A.; Brackett, D. J.; Postier,R. G. Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am. J. Surg. 2002, 184 (6), 642-647, discussion 647-648.
57. Boss, E. A.; Peters, W. H.; Roelofs, H. M.; Boonstra, H.; Steegers, E. A.; Massuger, L. F. Glutathione S-transferases P1-1 and A1-1 in ovarian cyst fluids. Eur. J. Gynaecol. Oncol. 2001, 22 (6), 427-432.
58. Hough, C. D.; Sherman-Baust, C. A.; Pizer, E. S.; Montz, F. J.; Im, D. D.; Rosenshein, N. B.; Cho, K. R.; Riggins, G. J.; Morin, P. J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60 (22), 6281-6287.
59. Chen, Y. C.; Pohl, C.; Wang, T. L.; Morin, P. J.; Risberg, B.; Kristensen, G. B.; Yu, A.; Davidson, B.; Shih Ie, M. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 2005, 65 (1), 331-337.
60. Tavazoie, S. F.; Alvarez, V. A.; Ridenour, D. A.; Kwiatkowski, D. J.; Sabatini, B. L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 2005, 8 (12), 1727-1734.
61. Wang, W.; Mouneimne, G.; Sidani, M.; Wyckoff, J.; Chen, X.; Makris, A.; Goswami, S.; Bresnick, A. R.; Condeelis, J. S. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J. Cell Biol. 2006, 173 (3), 395-404.
62. Mataraza, J. M.; Briggs, M. W.; Li, Z.; Entwistle, A.; Ridley, A. J.; Sacks, D. B. IQGAP1 promotes cell motility and invasion. J. Biol. Chem. 2003, 278 (42), 41237-41245.
63. Meng, X.; Krokhin, O.; Cheng, K.; Ens, W.; Wilkins, J. A. Characterization of IQGAP1-containing complexes in NK-like cells: evidence for Rac 2 and RACK1 association during homotypic adhesion. J. Proteome Res. 2007, 6 (2), 744-750.
64. Yamaoka-Tojo, M.; Ushio-Fukai, M.; Hilenski, L.; Dikalov, S. I.; Chen, Y. E.; Tojo, T.; Fukai, T.; Fujimoto, M.; Patrushev, N. A.; Wang, N.; Kontos, C. D.; Bloom, G. S.; Alexander, R. W. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species - dependent endothelial migration and proliferation. Circ. Res. 2004, 95 (3), 276-283.
65. Yamaoka-Tojo, M.; Tojo, T.; Kim, H. W.; Hilenski, L.; Patrushev, N. A.; Zhang, L.; Fukai, T.; Ushio-Fukai, M. IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis. Arterioscler., Thromb., Vasc. Biol. 2006, 26 (9), 1991-1997.
66. Babcock, G.; Rubenstein, P. A. Control of profilin and Actin expression in muscle and nonmuscle cells. Cell Motil. Cytoskeleton 1993, 24 (3), 179-188.
67. Moldovan, N. I.; Milliken, E. E.; Irani, K.; Chen, J.; Sohn, R. H.; Finkel, T.; Goldschmidt-Clermont, P. J. Regulation of endothelial cell adhesion by profilin. Curr. Biol. 1997, 7 (1), 24-30.
68. Roy, P.; Jacobson, K. Overexpression of profilin reduces the migration of invasive breast cancer cells. Cell Motil. Cytoskeleton 2004, 57 (2), 84-95.
69. Luza, S. C.; Speisky, H. C. Liver copper storage and transport during development: implications for cytotoxicity. Am. J. Clin. Nutr. 1996, 63 (5), 812S-820S.
70. Kluger, H. M.; Kluger, Y.; Gilmore-Hebert, M.; DiVito, K.; Chang, J. T.; Rodov, S.; Mironenko, O.; Kacinski, B. M.; Perkins, A. S.; Sapi, E. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab. Invest. 2004, 84 (3), 320-331.
71. Sergeev, A. I.; Naidich, V. I.; Bunto, T. V. [Study of the kinetics of ascitic tumor development by proton magnetic relaxation]. Dokl. Akad. Nauk SSSR 1978, 238 (4), 974-976.
72. Vachtenheim, J.; Pavel, S.; Duchon, J. Dopa oxidase activity and ceruloplasmin in the sera of hamsters with melanoma. Neoplasma 1981, 28 (1), 59-65.
73. Yeshowardhana; Singh, V. S. Significance of serum phosphohexose isomerase, hexokinase and aldolase in carcinoma ovary. Indian J. Physiol. Pharmacol. 1985, 29 (1), 51-54.
74. Torimura, T.; Ueno, T.; Kin, M.; Harada, R.; Nakamura, T.; Kawaguchi, T.; Harada, M.; Kumashiro, R.; Watanabe, H.; Avraham, R.; Sata, M. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins. Hepatology 2001, 34 (1), 62-71.
75. Haga, A. [Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm]. Yakugaku Zasshi 2005, 125 (2), 169-175.
76. Leto, G.; Gebbia, N.; Rausa, L.; Tumminello, F. M. Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res. 1992, 12 (1), 235-240.
77. Losch, A.; Schindl, M.; Kohlberger, P.; Lahodny, J.; Breitenecker, G.; Horvat, R.; Birner, P. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol. Oncol. 2004, 92 (2), 545-552.
78. de Angelis, P. M.; Fjell, B.; Kravik, K. L.; Haug, T.; Tunheim, S. H.; Reichelt, W.; Beigi, M.; Clausen, O. P.; Galteland, E.; Stokke, T. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int. J. Oncol. 2004, 24 (5), 1279-1288.
79. Ozalp, S.; Tanir, H. M.; Yalcin, O. T.; Kabukcuoglu, S.; Oner, U.; Uray, M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur. J. Gynaecol. Oncol. 2003, 24 (5), 417-420.
80. Bachvarov, D.; L'Esperance, S.; Popa, I.; Bachvarova, M.; Plante, M.; Tetu, B. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int. J. Oncol. 2006, 29 (4), 919-933.
81. Jazaeri, A. A.; Awtrey, C. S.; Chandramouli, G. V.; Chuang, Y. E.; Khan, J.; Sotiriou, C.; Aprelikova, O.; Yee, C. J.; Zorn, K. K.; Birrer, M. J.; Barrett, J. C.; Boyd, J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin. Cancer Res. 2005, 11 (17), 6300-6310.
82. Spentzos, D.; Levine, D. A.; Kolia, S.; Otu, H.; Boyd, J.; Libermann, T. A.; Cannistra, S. A. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J. Clin. Oncol. 2005, 23 (31), 7911-7918.
83. Le Moguen, K.; Lincet, H.; Deslandes, E.; Hubert-Roux, M.; Lange, C.; Poulain, L.; Gauduchon, P.; Baudin, B. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 2006, 6 (19), 5183-5192.
84. Stewart, J. J.; White, J. T.; Yan, X.; Collins, S.; Drescher, C. W.; Urban, N. D.; Hood, L.; Lin, B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 2006, 5 (3), 433-443.
85. States, D. J.; Omenn, G. S.; Blackwell, T. W.; Fermin, D.; Eng, J.; Speicher, D. W.; Hanash, S. M. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 2006, 24 (3), 333-338.